Preclinical pharmacokinetics of SB-203580, a potent inhibitor of p38 mitogen-activated protein kinase

K. W. Ward Preclinical Drug Discovery, Cardiovascular, Urogenitary, and Oncology Centre for Excellence in Drug Discovery, and

J. W. Proksch Preclinical Drug Discovery, Cardiovascular, Urogenitary, and Oncology Centre for Excellence in Drug Discovery, and

L. M. Azzarano Preclinical Drug Discovery, Cardiovascular, Urogenitary, and Oncology Centre for Excellence in Drug Discovery, and

J. A. Mumaw Preclinical Drug Discovery, Cardiovascular, Urogenitary, and Oncology Centre for Excellence in Drug Discovery, and

T. J. Roethke Preclinical Drug Discovery, Cardiovascular, Urogenitary, and Oncology Centre for Excellence in Drug Discovery, and

G. J. Stelman Preclinical Drug Discovery, Cardiovascular, Urogenitary, and Oncology Centre for Excellence in Drug Discovery, and

M. J. Walsh Preclinical Drug Discovery, Cardiovascular, Urogenitary, and Oncology Centre for Excellence in Drug Discovery, and

K. S. Zeigler Preclinical Drug Discovery, Cardiovascular, Urogenitary, and Oncology Centre for Excellence in Drug Discovery, and

J. E. McSurdy-Freed Preclinical Drug Discovery, Cardiovascular, Urogenitary, and Oncology Centre for Excellence in Drug Discovery, and

J. R Kehler Preclinical Drug Discovery, Cardiovascular, Urogenitary, and Oncology Centre for Excellence in Drug Discovery, and

J. Chokshi Preclinical Drug Discovery, Cardiovascular, Urogenitary, and Oncology Centre for Excellence in Drug Discovery, and

M. A. Levy Preclinical Drug Discovery, Cardiovascular, Urogenitary, and Oncology Centre for Excellence in Drug Discovery, and

B. R. Smith Preclinical Drug Discovery, Cardiovascular, Urogenitary, and Oncology Centre for Excellence in Drug Discovery, and

Articles from other publishers (14)